Saturday 17 October 2026
Export JANX’s income statement to Excel — free account
Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.
16.49
0.83
−4.79%
Follow JANX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 2 |
+8 more TTM periods Free account |
| (10.70%) | (11.72%) | (11.48%) | (12.48%) | ||
| (10.06%) | (11.01%) | (11.02%) | (11.85%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(11.07%) | (12.09%) | (11.90%) | (10.46%) | |
Average Days of Receivables |
2.27 | 901.43 | — | 0.00 | |
Free Cash Flow per Share |
(0.67) | (1.25) | (1.34) | (1.15) | |
Free Cash Flow |
(41.92) | (78.49) | (83.28) | (71.40) | |
Capital Expenditures |
(0.67) | (0.94) | (1.04) | (0.98) | |
| Other line items | |||||
Cash ROIC |
(2.21%) | (4.14%) | (4.33%) | (3.63%) | |
Accounts Receivable Turnover |
25.96 | 0.78 | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
516.60% | 900.75% | 0.00% | 595.54% | |
Selling, General and Administrative Expense of Revenue |
181.55% | 303.85% | 0.00% | 202.39% | |
Share Based Compensation of Revenue |
153.71% | 273.69% | 0.00% | 191.13% | |
Operating CF/Net income |
0.40 | 0.68 | 0.72 | 0.69 | |
Depreciation/Fixed assets |
(3.61) | (3.95) | (4.04) | (3.45) | |
Capex/Depreciation |
0.06 | 0.07 | 0.07 | 0.07 | |
Revenue per Share |
0.38 | 0.23 | 0.00 | 0.31 | |
Operating CF per Share |
(0.66) | (1.24) | (1.33) | (1.14) | |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.02) | |
Capex to Sales |
0.03 | 0.07 | 0.00 | 0.05 |
Columns are period end dates